Navigation Links
TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
Date:5/13/2008

d, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of the company's product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of the company's product candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel or NGX426 will successfully treat migraine and/or other indications for which they are developed, that the End of Phase II meeting will be held in the anticipated time frame, that NGX267 will successfully treat xerostomia secondary to Sjogren's syndrome, that the company's gamma secretase modulators will be able to successfully treat Alzheimer's disease or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel, NGX426 or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company Contact: Media Contact:

Craig Johnson David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x158 212-845-4271


SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
2. TorreyPines Therapeutics to Present at BMO Capital Markets Focus on Healthcare Conference
3. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
4. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
5. Prime Therapeutics Receives TIPPS Certification
6. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
7. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
8. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
9. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
10. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
11. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Volpara Solutions announced today that it ... Annual Meeting of the Radiology Society of North ... 1752 – South Hall). Volpara Solutions will showcase ... of its innovative suite of quantitative breast imaging ... measurements of volumetric density, patient-specific dose, breast compression ...
(Date:11/24/2014)... Recently, SweetDressy.com, a well-known dress supplier and leader in ... Evening Dresses. All these fresh items are offered at ... the special offer is valid until Dec. 20, 2014. ... been working well in the fashion industry for years. ... new dresses may be the best products for many ...
(Date:11/24/2014)... 2014 SafeHandles™ announced that they will ... Ed Begley Jr, airing via Discovery Channel. Dates and ... a passive, non-invasive, replaceable, and affordable germ protective device. ... shrinkable sleeves and adhesives to promote hand hygiene in ... core of SafeHandles is the desire to make a ...
(Date:11/23/2014)... The clinical trial report, "Aspergillosis ... on the Aspergillosis clinical trial scenario. This report ... clinical trials on Aspergillosis. It includes an overview ... as per the site of trial conduction across ... of disease clinical trials by their phase, trial ...
(Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water tank company, ... 8 year warranty on its selected hot water tanks. As ... to the impending winter season, it was important for Pro ... that the company provides. As a result, Pro Ace will ... Bradford hot water tanks. , “Every installer who works ...
Breaking Medicine News(10 mins):Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
... people who are unlikely to incur high medical expenses. ... families, finds a study of Massachusetts families from Children,s ... Care and Prevention (DACP). The study appears in the ... The researchers, led by Alison Galbraith, MD, MPH, and ...
... survive severe injuries on battlefields such as those in ... infections of their wounds with multidrug resistant bacteria. The ... Staphylococcus aureus (MRSA), Acinetobacter baumannii , ... coli . , Dr Clinton K. Murray, from Brooke ...
... to create open access to information that will enhance ... ORLANDO, Fla., March 29 /PRNewswire/ -- ... GE Healthcare,s Cardiovascular Ultrasound unit announced a formal affiliation ... an integrated solution aimed at improving workflow for echocardiography ...
... allergen breathed in by a person with asthma triggers a ... events to prompt an allergic reaction, said a consortium of ... in Houston in a report that appears online today in ... activates interleukin 25, a key mediator of the allergic response ...
... Relaxin cuts shortness of breath and trimmed hospital stays, phase ... The hormone relaxin reduces shortness of breath and cardiovascular death ... pressure, according to a phase 2 trial conducted in eight ... a few hours of arriving at a hospital, were randomly ...
... Doctor urges first responders to clean equipment regularly ... News) -- One in three stethoscopes used by ... methicillin-resistant Staphylococcus aureus (MRSA) bacteria, a new study ... and Dentistry of New Jersey swabbed 50 stethoscopes ...
Cached Medicine News:Health News:Low-income families with sick children often enrolled in high-deductible health care plans 2Health News:ProSolv CardioVascular and GE Healthcare Ultrasound Division Announce Affiliation 2Health News:ProSolv CardioVascular and GE Healthcare Ultrasound Division Announce Affiliation 3Health News:Hormone Reduces Mortality in Heart Patients With High BP 2Health News:Third of EMS Stethoscopes Carry MRSA Bacterium 2
(Date:11/24/2014)...  Pifflers United Chronic and Invisible Illnesses Support ... results of a study of ActiPatch®, a new ... fibromyalgia pain. The results demonstrated that when used ... clinically meaningful pain reduction can be achieved. ... used ActiPatch® for 7 days and were then ...
(Date:11/23/2014)... DAYTON, N.J. , Nov. 23, 2014  Aurobindo ... lot GESB14011-A of Gabapentin Capsules, USP 300 mg 100-count ... been found to contain some empty capsules. ... resulting in adverse health consequences that could range from ... withdrawal effect, or status epilepticus (long period seizures) that ...
(Date:11/22/2014)... Nov. 21, 2014  CytoSorbents Corporation (OTCQB: CTSO), ... Union approved CytoSorb® cytokine adsorber to treat critically-ill ... Beacon of Light Award at last night,s New ... Dr. Phillip Chan , Chief Executive ... to be recognized by the New Jersey Tech ...
Breaking Medicine Technology:Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
Inquire...
Inquire...
Inquire...
... a range of 18 Ophthalmic frames ... and producted to the very hightest ... super lightweight Titanium and Beta Titanium ... host of beautifully formed and innovative ...
Medicine Products: